Dark

GALT
Galectin Therapeutics Inc.
stock NASDAQ

At Close

Jun 18, 2025 3:59:32 PM EDT

3.26USD+36.402%(+0.87)5,406,587

0.00Bid 0.00Ask 0.00Spread

Pre-market

Jun 18, 2025 9:26:30 AM EDT

2.39USD0.000%(0.00)24,652

After-hours

Jun 18, 2025 4:58:30 PM EDT

3.28USD+0.613%(+0.02)56,772

OverviewOptionsHistoricalExchangesShortsNews

Jan 6, 2022

08:00AM EST Galectin Therapeutics to Present at the H.C. Wainwright BioConnect GlobeNewswire Inc

Dec 21, 2021

08:00AM EST Galectin Therapeutics Announces Closing of $10 Million in Debt GlobeNewswire Inc

Dec 13, 2021

08:10AM EST Galectin Therapeutics Discusses Corporate Transformation, Progress Of NAVIGATE Trial And Outlines Strategy For Potential Phase 2 Cancer Immunotherapy Trial At Annual Meeting Benzinga

08:00AM EST NAVIGATE clinical trial in NASH cirrhosis now underway in all countries originally selected; full enrollment expected by mid-2022 GlobeNewswire Inc

Nov 15, 2021

11:02AM EST Galectin Therapeutics Q3 EPS $(0.14) Down From $(0.10) YoY Benzinga

08:00AM EST Board approves exploration of a Company-sponsored belapectin oncology program complementing our ongoing NASH cirrhosis program GlobeNewswire Inc

Nov 5, 2021

04:25PM EDT UPDATE Galectin Therapeutics to Present Six GlobeNewswire Inc

Oct 27, 2021

08:03AM EDT Galectin Pharmaceuticals To Present 6 Scientific Abstracts At The Liver Meeting 2021, Hosted By AASLD Benzinga

08:00AM EDT Galectin Pharmaceuticals to Present Six Scientific Abstracts at GlobeNewswire Inc

Oct 5, 2021

03:40PM EDT Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 5th Annual NASH Investor Conference being held virtually on October 12, 2021. GlobeNewswire Inc

01:55PM EDT Galectin Therapeutics to Participate in the H.C. Wainwright 23rd GlobeNewswire Inc

Sep 21, 2021

08:00AM EDT Galectin Therapeutics Announces $20 Million Convertible Debt GlobeNewswire Inc

Sep 9, 2021

09:00AM EDT Galectin Therapeutics, Inc. to Participate in the H.C. Wainwright GlobeNewswire Inc

Aug 30, 2021

08:00AM EDT Galectin Therapeutics Strengthens Leadership Team with Strategic GlobeNewswire Inc

Aug 16, 2021

09:06AM EDT Galectin Therapeutics Q2 EPS $(0.15) Down From $(0.11) YoY Benzinga

09:00AM EDT Galectin Therapeutics Reports Financial Results for the Quarter GlobeNewswire Inc

Jul 9, 2021

02:38PM EDT Mid-Afternoon Market Update: Dow Jumps Over 400 Points; Sigilon Therapeutics Shares Plummet Benzinga

11:14AM EDT Mid-Morning Market Update: Markets Open Higher; AZZ Reports Upbeat Q1 Results Benzinga

09:25AM EDT Galectin Therapeutics Stock Surges After Robust Data From Belapectin/Keytruda Combo In Melanoma, Head & Neck Cancer Benzinga

08:02AM EDT UPDATE: Galectin Says Balpectin, KEYTRUDA Combo Showed Cancer Control Rate 56% In Melanoma, 40% In Head And Neck Cancer Benzinga

08:01AM EDT Galectin Therapeutics Reports Top-Line Results From Phase 1b Trial Extension Of Belapectin In Combo With KEYTRUDA In Advanced Metastatic Melanoma, Head And Neck Cancer Benzinga

08:00AM EDT Galectin Therapeutics Announces Positive Top-Line Results from a GlobeNewswire Inc

May 17, 2021

10:23AM EDT Galectin Therapeutics shares were trading lower after the company reported Q1 EPS results down from last year. Benzinga

08:00AM EDT Galectin Therapeutics Reports Financial Results for the Quarter GlobeNewswire Inc

07:59AM EDT Galectin Therapeutics Q1 EPS $(0.11) Down From $(0.06) YoY Benzinga

Apr 30, 2021

07:31AM EDT The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs Benzinga

Apr 29, 2021

08:15AM EDT The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx Benzinga

Apr 27, 2021

09:28AM EDT Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Pol F. Boudes, M.D., Chief Medical Officer, will present the belapectin program at the 4th Global NASH Congress taking place virtually on April 28 and 29, 2021. GlobeNewswire Inc

07:41AM EDT The Daily Biotech Pulse: Lilly, Novartis Trail Q1 Estimates, Exec Departure At Applied Genetics, Patent Award For Scholar Rock, Aldeyra Data Readout Benzinga

Apr 23, 2021

07:28AM EDT The Daily Biotech Pulse: Quidel Slides On Negative Pre-Announcement, Roche Gets Positive EMA Committee Recommendation, 3 IPOs Benzinga

Apr 19, 2021

08:00AM EDT World-Renowned Neurosurgeon Dr. Ben Carson, Sr. Joins Galectin GlobeNewswire Inc

Apr 16, 2021

07:39AM EDT HC Wainwright & Co. Maintains Buy on Galectin Therapeutics, Raises Price Target to $14 Benzinga

Apr 14, 2021

10:30AM EDT Mid-Morning Market Update: Markets Open Higher; JPMorgan Beats Q1 Views Benzinga

08:28AM EDT Galectin Therapeutics Stock Is Trading Higher After Belapectin-Pembrolizumab Combo Study Shows Enhanced Tumor Response Benzinga

05:20AM EDT Galectin Therapeutics Shares Up 36% Premarket; Co Announced Late Tuesday Journal for ImmunoTherapy of Cancer Publishes Phase 1 Clinical Research Shows Galectin-3 Inhibitor Belapectin Enhances Tumor Response in Combination with Anti-PD-1 Therapy Benzinga

Apr 13, 2021

07:01PM EDT Journal for ImmunoTherapy of Cancer Publishes Phase 1 Clinical GlobeNewswire Inc

Apr 6, 2021

10:58AM EDT Insider Buys Galectin Therapeutics Stock Benzinga

08:09AM EDT Galectin Therapeutics Highlights Launch Of NAVIGATEnash.com, Resource For Patients, Physicians About Its NASH Cirrhosis Study Benzinga

08:00AM EDT Galectin Therapeutics Launches NAVIGATEnash.com, a Resource for GlobeNewswire Inc

Apr 1, 2021

07:26AM EDT Galectin Therapeutics Filed US Patent Application #20210093656 Composition of Novel Carbohydrate Drug for Treatment of Human Diseases Benzinga

Mar 31, 2021

11:31AM EDT Galectin Therapeutics Granted EU Patent Titled 'COMPOSITIONS FOR THE TREATMENT OF STEATOHEPATITIS AND FATTY LIVER DISEASE' Benzinga

08:15AM EDT Galectin Therapeutics FY20 EPS $(0.41), Down From $(0.39) YoY Benzinga

08:14AM EDT Galectin Therapeutics FY 2020 EPS $(0.41) Vs $(0.43) Est. Benzinga

08:12AM EDT Galectin Therapeutics Gives Business Update (Full Statement From CEO) Benzinga

08:00AM EDT Galectin Therapeutics Reports Fiscal 2020 Financial Results and GlobeNewswire Inc

Mar 8, 2021

08:46AM EST OncoImmunology Publishes Pre-clinical Research Showing Galectin GlobeNewswire Inc

08:05AM EST Galectin Therapeutics Says OncoImmunology Publishes Pre-Clinical Research Showing Co's Belapectin Galectin-3 Inhibitor Reduces Tumor Progression In Combination With Anti-OX40 Therapy Benzinga

Mar 4, 2021

08:00AM EST Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Pol Boudes, M.D., Chief Medical Officer, will provide a corporate overview at the upcoming H.C. Wainwright Global Life Sciences Conference to be held March 9-10, 2021. GlobeNewswire Inc

Jan 19, 2021

11:16AM EST Insider Sells Galectin Therapeutics Stock Benzinga

Dec 11, 2020

08:00AM EST Galectin Therapeutics, Inc. to Present at the 4th Annual Digital GlobeNewswire Inc

Dec 4, 2020

04:17PM EST Galectin Therapeutics Inc. Recaps Results of Annual Meeting of GlobeNewswire Inc

Dec 1, 2020

08:00AM EST Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that management will present a corporate update via live webcast immediately following the business portion of its 2020 Annual Meeting of Stockholders to be held on Thursday, December 3, 2020, beginning at 11:00 a.m. EST. GlobeNewswire Inc

Nov 9, 2020

08:00AM EST Galectin Therapeutics Provides Business UpdateAnd GlobeNewswire Inc

07:51AM EST Galectin Therapeutics Q3 EPS $(0.10) Down From $(0.05) YoY Benzinga

Sep 29, 2020

12:00PM EDT Galectin Therapeutics Inc.(NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced that the Company will host an investor conference call and webinar to discuss the Companys NASH-RX clinical trial and to introduce its new CEO, Joel Lewis. The Investor Call is scheduled for today at 4:00 p.m. EDT. GlobeNewswire Inc

Sep 22, 2020

08:04AM EDT Galectin Therapeutics Inc.(NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that the Company will host an investor conference call and webinar to discuss the Companys NASH-RX clinical trial and to introduce its new CEO, Joel Lewis. The Investor Call is scheduled for Tuesday, September 29, 2020, at 4:00 p.m. EDT. GlobeNewswire Inc

Sep 10, 2020

08:00AM EDT Galectin Therapeutics Inc.(NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that management will present at theH.C. Wainwright 22nd Annual Virtual Global Investment Conference, onMonday, September 14, 2020, at12:30 p.m. EDT. GlobeNewswire Inc

Sep 9, 2020

11:46AM EDT Insider Buys Galectin Therapeutics Stock Benzinga

Sep 2, 2020

08:10AM EDT Galectin Therapeutics Names Joel Lewis CEO; Harold Shlevin Retires As CEO RTTNews

08:06AM EDT Galectin Therapeutics Appoints Joel Lewis As CEO Benzinga

08:00AM EDT Dr. Harold Shlevin retires as CEO, transitions to role of scientific and business consultant and will remain on the Board GlobeNewswire Inc

Aug 13, 2020

07:09AM EDT HC Wainwright & Co. Maintains Buy on Galectin Therapeutics, Raises Price Target to $12 Benzinga

Aug 10, 2020

08:08AM EDT Galectin Therapeutics Q2 EPS $(0.11) Misses $(0.09) Estimate Benzinga

08:00AM EDT Galectin Therapeutics Reports Financial Results for the Quarter GlobeNewswire Inc